Loading...
•
Sep 30, 2020
Rockwell Medical Q3 2020 Earnings Report
Reported financial results and business update for the three months ended September 30, 2020.
Key Takeaways
Rockwell Medical reported Q3 2020 revenue of $15.3 million and ended the quarter with $67.3 million in cash, cash equivalents and investments. The company is preparing for the U.S. commercial launch of Triferic® AVNU expected in Q1 2021 and anticipates enrolling the first patient in a Phase 3 clinical trial of Triferic in China.
Net sales for the concentrates business were $15.0 million.
Net sales for Triferic were $0.3 million.
Approximately 3,400 contracted patients on therapy, representing approximately 500,000 annualized treatments.
Cash, cash equivalents, and investments totaled $67.3 million as of September 30, 2020.
Forward Guidance
Rockwell Medical intends to use the net proceeds to advance the development of FPC, currently indicated for the maintenance of hemoglobin in dialysis, in new indications, including for the treatment of anemia in the home infusion setting, as well as for working capital and general corporate purposes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...